Nanobiotix is taking advantage of the ability of nanoparticles to absorb and transform energy to treat cancer. The company's nanoXray technology uses standard x-ray to activate injected cell-targeting non-drug nanoparticles. Today, Nanobiotix is focused solely on cancer applications of its technology, but the company believes there are other targets for the technology, including cardiovascular diseases.
60 avenue Wattignies
75012 Paris, France
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.